Abeona Therapeutics Inc (NASDAQ:ABEO) SVP Brendan M. O’malley Sells 25,734 Shares of Stock

Abeona Therapeutics Inc (NASDAQ:ABEO) SVP Brendan M. O’malley sold 25,734 shares of the company’s stock in a transaction on Monday, October 11th. The stock was sold at an average price of $0.90, for a total value of $23,160.60. The sale was disclosed in a filing with the SEC, which is accessible through this link.

NASDAQ:ABEO opened at $0.88 on Thursday. The stock has a market cap of $89.11 million, a price-to-earnings ratio of -1.52 and a beta of 1.43. The business has a fifty day moving average of $1.19 and a 200-day moving average of $1.44. Abeona Therapeutics Inc has a 1 year low of $0.84 and a 1 year high of $3.79.

Abeona Therapeutics (NASDAQ:ABEO) last announced its quarterly earnings data on Thursday, July 29th. The biopharmaceutical company reported ($0.16) earnings per share for the quarter, meeting the Thomson Reuters’ consensus estimate of ($0.16). Equities analysts expect that Abeona Therapeutics Inc will post -0.65 EPS for the current fiscal year.

Several institutional investors have recently made changes to their positions in the company. Morgan Stanley lifted its holdings in shares of Abeona Therapeutics by 242.6% in the second quarter. Morgan Stanley now owns 1,815,198 shares of the biopharmaceutical company’s stock valued at $2,833,000 after buying an additional 1,285,445 shares during the period. Meitav Dash Investments Ltd. lifted its holdings in shares of Abeona Therapeutics by 24.5% in the second quarter. Meitav Dash Investments Ltd. now owns 122,000 shares of the biopharmaceutical company’s stock valued at $190,000 after buying an additional 24,000 shares during the period. Millennium Management LLC acquired a new stake in shares of Abeona Therapeutics in the second quarter valued at $2,137,000. Boothbay Fund Management LLC purchased a new stake in shares of Abeona Therapeutics during the second quarter valued at $39,000. Finally, LMR Partners LLP purchased a new stake in shares of Abeona Therapeutics during the second quarter valued at $60,000. Institutional investors and hedge funds own 27.51% of the company’s stock.

Several research analysts have recently issued reports on ABEO shares. Zacks Investment Research cut Abeona Therapeutics from a “buy” rating to a “hold” rating in a research note on Wednesday, September 22nd. HC Wainwright reissued a “buy” rating and issued a $5.00 price target on shares of Abeona Therapeutics in a research note on Wednesday, October 6th. One investment analyst has rated the stock with a hold rating and four have given a buy rating to the company’s stock. According to MarketBeat.com, the stock presently has an average rating of “Buy” and an average target price of $3.65.

About Abeona Therapeutics

Abeona Therapeutics Inc, a clinical-stage biopharmaceutical company, focuses on developing and delivering gene therapy products for severe and life-threatening rare diseases. The company's lead programs are EB-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (RDEB); ABO-102, which are AAV based gene therapies for Sanfilippo syndrome type A; and ABO-101, an adeno-associated virus (AAV) based gene therapies for Sanfilippo syndrome type B.

Featured Article: Determine Your Level of Risk Tolerance

Insider Buying and Selling by Quarter for Abeona Therapeutics (NASDAQ:ABEO)

Receive News & Ratings for Abeona Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Abeona Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.